Table 1.

The patients' characteristics

Patient	Age	Sex	Duration (months)	H & Y	Side	UPDRS III	MMSE	Medication	cMRI	FP-CIT	Follow-up (months)
1	52	M	30	I–II	Ri	17	30	Rasagiline, pramipexole	Normal	+	28
2	64	M	30	II	Ri	11	30	Pramipexole	Normal	+	29
3	69	M	36	I	Le	16	30	Rasagiline	Normal	+	29
4	54	M	12	I	Le	12	30	Rasagiline	Normal	+	21
5	47	F	36	I–II	Ri	16	30	Rasagiline	Normal	n.d.	27
6	59	M	24	I	Le	17	30	Pramipexole	Normal	n.d.	21
7	60	F	15	I	Ri	11	30	Rasagiline, pramipexole	Normal	+	22
8	45	F	24	I–II	Ri	10	30	Pramipexole, l-Dopa	Normal	+	31
9	52	M	42	I–II	Ri	14	30	Rasagiline	Normal	+	44
10	44	M	36	I	Le	7	30	Rasagiline, pramipexole	Normal	+	53
11	72	M	11	I	Ri	6	30	None	Normal	+	21
12	42	M	18	I	Ri	10	30	None	Normal	n.d.	21
13	56	M	6	I	Ri	5	30	None	Normal	+	18
14	62	M	5	I	Le	6	30	None	Normal	+	18
15	63	F	12	I	Ri	12	30	None	Normal	+	24
16	56	M	6	I	Le	4	30	None	Normal	+	n.d.
17	71	F	6	I	Ri	5	30	None	Normal	+	20
18	51	M	24	I–II	Le	8	30	None	Normal	+	n.d.
19	71	F	24	I–II	Le	12	30	None	Normal	+	15
20	43	M	30	I	Le	13	30	None	Normal	+	27

Le = Left; Ri = Right; cMRI = cranial magnetic resonance imaging; H&Y = Hoehn & Yahr; n.d. = not determined.